Dilated Cardiomyopathy (DCM)

1. Topic Overview

Summary

Dilated Cardiomyopathy (DCM) is a myocardial disease characterised by left ventricular or biventricular dilation and systolic dysfunction in the absence of coronary artery disease, valvular disease, or other causes sufficient to explain the degree of dysfunction. [1] DCM is the most common cardiomyopathy and a leading indication for heart transplantation worldwide. [2] Genetic mutations account for 30-50% of cases, with titin (TTN) truncating variants being the most prevalent genetic cause. [3] Treatment follows standard heart failure with reduced ejection fraction (HFrEF) guidelines, with emphasis on genetic testing, family screening, and consideration of advanced therapies for refractory cases. [4]

Key Facts

• Definition: LV or biventricular dilation with LVEF less than 45% without sufficient coronary artery disease, valvular abnormality, or loading conditions to explain the dysfunction [1]
• Prevalence: Approximately 1 in 250-500 adults globally; most common cardiomyopathy requiring transplantation [2]
• Genetic Contribution: 30-50% have an identifiable genetic cause when comprehensive genetic testing is performed [3,5]
• Most Common Gene: TTN (titin) truncating variants account for 20-25% of familial DCM and 15-18% of sporadic cases [3]
• Prognosis: 5-year survival 50-80% depending on severity, aetiology, and treatment response; significant improvement with modern guideline-directed medical therapy [6]
• Treatment: Four-pillar HFrEF therapy (RAAS inhibition, beta-blockers, MRA, SGLT2 inhibitors); genetic testing and cascade family screening are Class I recommendations [4]

Clinical Pearls

High-Yield Points:

• Always exclude reversible causes: alcohol, thyroid disease, tachycardia-induced, peripartum, inflammatory, nutritional deficiencies
• Genetic testing is recommended for all DCM patients without obvious secondary cause (ESC 2023 guidelines Class I) [4]
• First-degree relatives require clinical screening with ECG and echocardiography [7]
• TTN truncating variants are most common but may have better prognosis than some other genetic forms [8]
• LMNA mutations carry exceptionally high arrhythmic risk - consider early ICD even with preserved EF [9]
• 25-40% of patients may demonstrate left ventricular reverse remodelling with optimal medical therapy, particularly those with recent-onset disease [10]
• Cardiac MRI with late gadolinium enhancement (LGE) provides powerful prognostic information; mid-wall LGE predicts adverse outcomes [11]
• Subclinical systolic dysfunction detectable by strain imaging in genotype-positive phenotype-negative relatives warrants close monitoring [21]

Why This Matters

DCM is a major cause of heart failure and sudden cardiac death, particularly in younger patients, affecting individuals during their most productive years. [2] Identifying reversible causes such as alcohol excess, tachycardia-mediated cardiomyopathy, or inflammatory myocarditis can lead to complete or partial recovery of cardiac function. [10] Genetic diagnosis enables cascade family screening, potentially identifying at-risk relatives before symptoms develop, allowing for early intervention and improved outcomes. [7] Understanding the heterogeneous nature of DCM - from genetic substrate to environmental triggers - is essential for personalised risk stratification and management. [5] Recent advances in genetic cardiomyopathy research have revealed novel therapeutic targets and genotype-specific management strategies. [22]

---

2. Epidemiology

Prevalence and Incidence

Geographic and Ethnic Variations

Regional Differences:

• Higher prevalence reported in African American populations compared to Caucasian populations [2]
• Peripartum cardiomyopathy shows geographic variation with highest rates in Sub-Saharan Africa (1:100 to 1:300 deliveries) [12]
• Chagas disease remains a leading cause of DCM in Central and South America [2]

Risk Factors and Causes

Genetic Causes (30-50% of all DCM)

Major DCM Genes: [3,5]

Inheritance Patterns:

• Predominantly autosomal dominant (90% of familial cases) [5]
• X-linked (DMD - Duchenne/Becker, EMD - Emery-Dreifuss) [5]
• Autosomal recessive (rare: SGCD, TCAP, TTN compound heterozygotes) [5]
• Mitochondrial (maternal inheritance, multi-system involvement) [5]

Acquired/Secondary Causes

Inflammatory/Infectious:

• Viral myocarditis (Coxsackie B, parvovirus B19, HHV-6, adenovirus) - post-inflammatory remodelling [13]
• Bacterial (Lyme disease, diphtheria)
• Parasitic (Chagas disease - Trypanosoma cruzi)
• Autoimmune/systemic (sarcoidosis, systemic lupus erythematosus, dermatomyositis)

Toxic:

• Alcohol - chronic consumption >80 g/day for >5 years [2]
• Cocaine and amphetamines [2]
• Chemotherapy: anthracyclines (cumulative dose-dependent), trastuzumab, tyrosine kinase inhibitors [14]
• Heavy metals (lead, mercury, cobalt)

Metabolic/Endocrine:

• Thyroid dysfunction (hypothyroidism or thyrotoxicosis) [2]
• Diabetes mellitus (diabetic cardiomyopathy)
• Phaeochromocytoma (catecholamine excess)
• Acromegaly (growth hormone excess)

Nutritional:

• Thiamine deficiency (beriberi, wet beriberi) [2]
• Selenium deficiency (Keshan disease)
• Carnitine deficiency

Tachycardia-Mediated:

• Uncontrolled atrial fibrillation (ventricular rate >110-120 bpm for prolonged periods) [15]
• Incessant supraventricular tachycardia
• Frequent ventricular ectopy (>10-15% burden) - arrhythmia-induced cardiomyopathy [21]

Pregnancy-Related:

• Peripartum cardiomyopathy (last month of pregnancy to 5 months postpartum) [12]
• Risk factors: multiparity, advanced maternal age, African descent, pre-eclampsia, multiple gestation

Idiopathic:

• 30-40% remain unexplained after comprehensive clinical, imaging, and genetic evaluation [2]

---

3. Pathophysiology

Molecular Mechanisms

Sarcomeric Dysfunction

TTN-Related Mechanisms: [3]

• Titin is a giant sarcomeric protein extending from Z-disc to M-line
• Truncating variants (nonsense, frameshift, splice-site mutations) lead to haploinsufficiency
• Impaired passive elasticity and length-sensing mechanisms
• Disrupted mechanotransduction pathways

Cytoskeletal Protein Defects:

• LMNA mutations disrupt nuclear envelope integrity [9]
• Impaired mechanotransduction between cytoskeleton and nucleus
• Abnormal gene regulation and cellular signaling
• Premature cellular senescence and increased apoptosis

Sarcomeric Protein Mutations:

• MYH7, TNNT2 mutations alter force generation and calcium sensitivity
• Impaired energy efficiency of contraction
• Overlap syndromes with hypertrophic cardiomyopathy possible

Cellular Pathophysiology

Cardiomyocyte Death Pathways:

1. Apoptosis - programmed cell death via intrinsic and extrinsic pathways
2. Necrosis - inflammatory cell death (myocarditis, ischemia)
3. Autophagy - dysregulated self-digestion of cellular components
4. Ferroptosis - iron-dependent lipid peroxidation

Myocyte Loss and Replacement:

• Progressive myocyte dropout reduces functional muscle mass
• Replacement fibrosis (collagen deposition) reduces compliance
• Interstitial fibrosis disrupts electrical coupling and promotes arrhythmias

Ventricular Remodeling Cascade

Phase 1: Initial Injury (Weeks to Months)

• Genetic defect or acquired insult triggers myocyte dysfunction
• Localized cell death and inflammatory response
• Compensatory hypertrophy of remaining myocytes

Phase 2: Eccentric Remodeling (Months to Years)

• Chamber dilation with increased end-diastolic and end-systolic volumes
• Wall thinning (relative to chamber size)
• Transition from elliptical to spherical chamber geometry
• Increased wall stress per Laplace's law: Wall Stress = (Pressure × Radius) / (2 × Wall Thickness)

Phase 3: Neurohormonal Activation (Ongoing)

• Renin-angiotensin-aldosterone system (RAAS) activation
• Sympathetic nervous system upregulation
• Natriuretic peptide release (BNP, NT-proBNP)
• Initially compensatory, becomes maladaptive with chronic activation

Phase 4: Progressive Dysfunction (Years)

• Vicious cycle: dilation → increased wall stress → further dilation
• Mitral annular dilation causes functional mitral regurgitation
• Increased filling pressures → pulmonary hypertension → right ventricular dysfunction
• End-organ hypoperfusion and congestion

Electrical Remodeling

Structural Substrate for Arrhythmias:

• Myocardial fibrosis creates re-entry circuits [11]
• Heterogeneous conduction velocities
• Increased dispersion of repolarization
• Spontaneous automaticity from abnormal calcium handling

Arrhythmogenic Mechanisms:

• Ventricular arrhythmias: re-entry in fibrotic substrate, triggered activity
• Atrial fibrillation: atrial dilation and fibrosis
• Conduction disease: fibrosis of conduction system (particularly LMNA mutations) [9]

Metabolic Derangements

Energy Substrate Utilization:

• Shift from fatty acid to glucose oxidation (less efficient)
• Mitochondrial dysfunction and impaired ATP production - key driver of DCM pathogenesis [23]
• Oxidative stress and reactive oxygen species (ROS) overproduction [24]
• Dysregulation of Ca²⁺ homeostasis and metabolic imbalance [24]
• Calcium handling abnormalities (SERCA dysfunction)
• Mitochondrial CaMKII activation causes adverse metabolic reprogramming, decreased ATP, elevated diastolic Ca²⁺, and reduced contractile performance [25]

Mitochondrial Pathophysiology: [23,24,25]

• Cardiolipin remodeling abnormalities (tafazzin mutations in Barth syndrome)
• Impaired oxidative phosphorylation and energy deficiency
• Reduced myocardial oxygen consumption efficiency [26]
• Progressive metabolic supply-demand mismatch

---

4. Clinical Presentation

Typical Presentation

Classic Heart Failure Syndrome:

Symptoms (Left Ventricular Failure):

• Exertional dyspnoea (progressive, NYHA Class I-IV) [2]
• Orthopnoea (dyspnoea when lying flat)
• Paroxysmal nocturnal dyspnoea (PND)
• Fatigue and exercise intolerance (impaired cardiac output)
• Palpitations (atrial or ventricular arrhythmias)
• Nocturnal cough (pulmonary venous congestion)
• Reduced exercise capacity and early fatigue

Symptoms (Right Ventricular Failure):

• Peripheral oedema (dependent areas)
• Abdominal discomfort and early satiety (hepatic congestion, ascites)
• Right upper quadrant pain (hepatic capsular stretch)
• Weight gain from fluid retention

Signs on Examination:

• Displaced apex beat (laterally and inferiorly beyond mid-clavicular line)
• Diffuse, hyperdynamic, or heaving apex
• S3 gallop rhythm (ventricular filling with elevated pressures)
• S4 gallop (atrial contraction against stiff ventricle, if sinus rhythm maintained)
• Pansystolic murmur at apex radiating to axilla (functional mitral regurgitation)
• Elevated jugular venous pressure (JVP) with prominent v waves (tricuspid regurgitation)
• Positive hepatojugular reflux
• Bibasal fine inspiratory crackles (pulmonary oedema)
• Reduced air entry at lung bases (pleural effusions)
• Bilateral pitting pedal oedema
• Cool extremities and prolonged capillary refill time (low cardiac output)
• Tender hepatomegaly
• Ascites (severe right heart failure)
• Cardiac cachexia (severe, chronic heart failure)

Atypical Presentations

Arrhythmia as First Manifestation:

• New-onset atrial fibrillation with rapid ventricular response [2]
• Sustained ventricular tachycardia or ventricular fibrillation
• Aborted sudden cardiac arrest (primary electrical event)
• Complete heart block or high-grade AV block (LMNA, LAMA4, SCN5A mutations) [9]
• Palpitations from frequent ventricular ectopy

Thromboembolic Events:

• Ischemic stroke from left ventricular or left atrial appendage thrombus [2]
• Peripheral arterial embolism
• Pulmonary embolism (from right heart thrombus or deep vein thrombosis due to immobility)
• May be first presentation in up to 10% of cases

Incidental Detection:

• Asymptomatic cardiomegaly on chest radiograph performed for other indication
• Reduced ejection fraction on routine echocardiography
• Abnormal ECG during pre-operative assessment or insurance medical
• Elevated natriuretic peptides on screening

Cascade Family Screening:

• Asymptomatic left ventricular dilation or dysfunction detected during screening of first-degree relatives [7]
• Allows early intervention before symptom development

Multi-System Presentations (Syndromic):

• Skeletal myopathy with cardiac involvement (LMNA, dystrophinopathies, DES) [9]
• Hearing loss (mitochondrial disorders)
• Developmental delay and dysmorphic features (metabolic disorders)
• Multi-organ involvement (sarcoidosis, hemochromatosis)

Age-Specific Presentations

Young Adults (20-40 years):

• More likely genetic or inflammatory aetiology [5]
• Peripartum cardiomyopathy in women [12]
• Athletic presentation with reduced performance
• Higher proportion of fulminant presentations

Middle-Aged Adults (40-60 years):

• Peak incidence age group [2]
• Mix of genetic and acquired aetiologies
• Often presents with classic heart failure syndrome
• May have prolonged asymptomatic phase before diagnosis

Older Adults (>60 years):

• Overlap with ischemic cardiomyopathy (must exclude coronary disease)
• Higher burden of comorbidities
• Atrial fibrillation more common at presentation
• May tolerate symptoms as "normal aging"

Red Flags - Immediate Action Required

EMERGENCY SITUATIONS:

Cardiogenic Shock:

• Hypotension (SBP less than 90 mmHg), cool peripheries, altered mental status
• Requires intensive monitoring, inotropic support, consideration of mechanical circulatory support

Sustained Ventricular Arrhythmias:

• VT/VF causing hemodynamic compromise
• Immediate cardioversion, anti-arrhythmic therapy, urgent ICD evaluation

Syncope:

• High-risk feature suggesting ventricular arrhythmia or high-grade AV block
• Urgent monitoring, risk stratification for sudden cardiac death
• Particularly concerning in LMNA mutations [9]

Acute Pulmonary Oedema:

• Acute decompensation with respiratory distress
• May require non-invasive ventilation or intubation
• Intensive diuresis and afterload reduction

Acute Stroke or Systemic Embolism:

• Suggests LV thrombus or atrial fibrillation
• Requires acute stroke protocol, imaging for thrombus, anticoagulation

High-Grade AV Block (Particularly LMNA):

• Progressive conduction disease can be rapid in LMNA [9]
• May require urgent temporary or permanent pacing

---

5. Clinical Examination

Systematic Cardiovascular Examination

Inspection

General Appearance:

• Respiratory distress (tachypnoea, use of accessory muscles, inability to speak in full sentences)
• Cachectic appearance (cardiac cachexia in chronic severe HF)
• Peripheral cyanosis (low cardiac output)
• Malar flush (mitral facies, rare in DCM)

Hands:

• Cool peripheries, prolonged capillary refill time (>2 seconds)
• Peripheral cyanosis
• Clubbing (rare, suggests associated lung disease or endocarditis)

Face and Eyes:

• Conjunctival pallor (anaemia)
• Xanthelasma or corneal arcus (lipid disorders, less relevant in DCM)
• Periorbital oedema

Pulse and Blood Pressure

Radial Pulse:

• Rate: Often tachycardic (compensatory mechanism or AF)
• Rhythm: Regular (sinus) or irregularly irregular (atrial fibrillation - common)
• Character: Small volume pulse (reduced stroke volume)
• Pulsus alternans (alternating strong and weak beats - severe LV dysfunction)

Blood Pressure:

• Often normal or low (low cardiac output)
• Narrow pulse pressure (reduced stroke volume)
• Postural hypotension (volume depletion from diuretics or autonomic dysfunction)

Jugular Venous Pressure

JVP Assessment:

• Elevated (>4 cm above sternal angle) - right heart failure or fluid overload
• Prominent v waves (functional tricuspid regurgitation)
• Positive hepatojugular reflux (sustained rise in JVP >3 cm with abdominal pressure)
• Kussmaul's sign (rise in JVP with inspiration - constrictive physiology, rare in DCM)

Precordial Examination

Inspection:

• Visible apex beat displaced laterally and inferiorly
• Parasternal heave (right ventricular enlargement from pulmonary hypertension)

Palpation:

• Apex beat: Displaced laterally beyond mid-clavicular line, displaced inferiorly (below 5th intercostal space)
• Character: Diffuse, sustained, hyperdynamic (volume overload), or heaving (pressure overload - less typical)
• Parasternal heave (RV enlargement)
• Palpable thrill at apex (severe mitral regurgitation, uncommon)

Auscultation:

• S1: Normal or soft (reduced contractility)
• S2: May have loud P2 (pulmonary hypertension)
• S3 gallop - low-pitched sound in early diastole (rapid ventricular filling with elevated diastolic pressures) - hallmark of heart failure
• S4 gallop - late diastolic sound (atrial contraction against stiff ventricle) - only if sinus rhythm maintained
• Systolic murmur: Pansystolic murmur at apex radiating to axilla (functional mitral regurgitation from annular dilation)
• Tricuspid regurgitation murmur at left sternal edge (increases with inspiration - Carvallo's sign)

Respiratory Examination

Inspection:

• Tachypnoea (>20 breaths/minute)
• Use of accessory muscles
• Orthopnoea (patient sitting upright, using multiple pillows)

Percussion:

• Dullness at lung bases (pleural effusions)

Auscultation:

• Bibasal fine inspiratory crackles (pulmonary oedema)
• Reduced breath sounds at bases (pleural effusions)
• Bronchial breathing above effusion (compressed lung)

Abdominal Examination

Inspection:

• Distension (ascites)
• Visible venous engorgement

Palpation:

• Tender hepatomegaly (right heart failure, hepatic congestion)
• Pulsatile liver (severe tricuspid regurgitation)
• Splenomegaly (chronic passive congestion, rare)
• Shifting dullness or fluid thrill (ascites)

Peripheral Examination

Lower Limbs:

• Bilateral pitting pedal oedema (dependent areas - ankles, sacrum if bed-bound)
• Severity: Mild (ankle), moderate (mid-shin), severe (thigh, scrotum)
• Skin changes from chronic venous congestion (hyperpigmentation, varicose eczema)
• Peripheral pulses (assess for peripheral vascular disease)

Neuromuscular (if syndromic features suspected):

• Proximal muscle weakness (LMNA, dystrophinopathies, myotonic dystrophy) [9]
• Wasting (particularly shoulder girdle and pelvic muscles)
• Myotonia (myotonic dystrophy - grip myotonia, percussion myotonia)
• Calf pseudohypertrophy (Duchenne/Becker muscular dystrophy)

---

6. Investigations

Essential First-Line Investigations

Electrocardiography (ECG)

Common Findings: [2]

• Sinus tachycardia (compensatory response)
• Atrial fibrillation (20-30% at presentation, higher with disease progression)
• Left ventricular hypertrophy (voltage criteria, strain pattern)
• Left bundle branch block (LBBB) - 15-30% of DCM patients
• Poor R wave progression (V1-V4) - may mimic anterior MI
• Non-specific ST-T wave changes
• Low voltage (diffuse myocardial disease)
• Q waves (may mimic prior MI in absence of coronary disease)
• Ventricular ectopy (frequent PVCs)

Gene-Specific ECG Patterns:

• LMNA mutations: Progressive conduction disease, first-degree AV block, LBBB, complete heart block [9]
• DM1 (myotonic dystrophy): Progressive AV block, atrial arrhythmias
• LAMP2 (Danon disease): Short PR interval, pre-excitation (WPW pattern), ventricular hypertrophy
• EMD (Emery-Dreifuss): Atrial standstill, junctional rhythm

Prognostic ECG Features:

• QRS duration >120 ms - predicts adverse outcomes
• LBBB - CRT candidate if EF ≤35%
• Fragmented QRS - suggests myocardial scar, arrhythmic risk

Transthoracic Echocardiography (TTE)

Essential for Diagnosis: [1,2]

Structural Assessment:

• Left ventricular dimensions:
  • LV end-diastolic dimension (LVEDD) >55-60 mm (absolute) or indexed to BSA
  • LV end-diastolic volume (LVEDV) >97 mL/m² (men) or >90 mL/m² (women)
  • LV end-systolic volume (LVESV) increased
• Wall thickness: Normal or thinned (eccentric remodeling)
• Chamber sphericity: Transition from elliptical to spherical geometry
• Right ventricular size and function: RV dilation and dysfunction in advanced disease

Functional Assessment:

• Left ventricular ejection fraction (LVEF): less than 40-45% (defines reduced EF)
  • "Mild reduction: 40-50%"
  • "Moderate reduction: 30-39%"
  • "Severe reduction: less than 30%"
• Global longitudinal strain (GLS): More sensitive than LVEF, abnormal if >-18%
• Diastolic function: Grading (I-III), elevated filling pressures (E/e' >14)

Valvular Assessment:

• Functional mitral regurgitation: Secondary to annular dilation and papillary muscle displacement
  • "Severity: Mild, moderate, severe"
  • "Mechanism: Central jet, incomplete leaflet coaptation"
• Tricuspid regurgitation: Common with RV dilation
• Exclusion of primary valvular disease as cause of LV dysfunction

Additional Parameters:

• Left atrial size (predicts AF, prognosis)
• Pulmonary artery systolic pressure (PASP) estimation
• LV thrombus detection (apical views, contrast if needed)
• Pericardial effusion (uncommon unless acute myocarditis)

Serial Echo for Monitoring:

• Assess response to medical therapy (reverse remodeling)
• Re-evaluation at 3-6 months after therapy optimization
• Annual follow-up if stable

Natriuretic Peptides

BNP and NT-proBNP: [2]

• Diagnostic value: Elevated in heart failure (stretching of myocardium)
• NT-proBNP thresholds:
  • less than 125 pg/mL: Heart failure unlikely
  • 125-300 pg/mL: Intermediate (further investigation)
  • >300 pg/mL: Heart failure likely (acute presentation)
  • >900 pg/mL: High probability
• BNP thresholds:
  • less than 35 pg/mL: Heart failure unlikely
  • >100 pg/mL: Heart failure likely

Prognostic Value:

• Higher levels predict worse outcomes
• Serial measurements guide therapy optimization
• Failure to decrease with treatment suggests poor prognosis

Confounders:

• Higher in elderly, women, renal impairment, AF
• Lower in obesity (adipose tissue clearance)

Blood Tests - Comprehensive Panel

Baseline Investigations:

• Complete blood count: Anaemia (worsens HF), infection
• Urea and electrolytes: Renal function (baseline, nephrotoxic drugs), electrolyte imbalance (K+, Mg2+, Na+)
• Liver function tests: Hepatic congestion, exclude hepatic disease
• Thyroid function (TSH, free T4): Exclude hypo/hyperthyroidism [2]
• Glucose and HbA1c: Diabetes mellitus
• Lipid profile: Cardiovascular risk assessment
• Troponin: May be mildly elevated (ongoing myocyte injury); marked elevation suggests acute myocarditis
• C-reactive protein (CRP) and ESR: Inflammation (myocarditis, systemic disease)

Specialized Tests (Based on Clinical Context):

• Ferritin, transferrin saturation, genetic testing for HFE: Hemochromatosis [2]
• Serum ACE, 24-hour urinary calcium: Sarcoidosis
• Auto-antibody screen: Systemic autoimmune disease (ANA, anti-dsDNA, anti-Scl-70, etc.)
• HIV serology: HIV-associated cardiomyopathy
• Chagas serology: If endemic area or relevant travel history
• Toxicology screen: Cocaine, amphetamines if suspected

Chest Radiograph

Typical Findings:

• Cardiomegaly (cardiothoracic ratio >50%)
• Pulmonary venous congestion (upper lobe blood diversion)
• Interstitial oedema (Kerley B lines - horizontal lines at costophrenic angles)
• Alveolar oedema (bilateral perihilar "bat-wing" shadowing)
• Pleural effusions (bilateral, right >left)

Utility:

• Initial assessment of heart size and pulmonary oedema
• Monitor response to diuretic therapy
• Exclude alternative pathology (pneumonia, malignancy, pneumothorax)

Advanced/Specialist Investigations

Coronary Angiography (Invasive or CT)

Indications: [4]

• Mandatory to exclude obstructive coronary artery disease as cause of LV dysfunction
• Particularly in patients with cardiovascular risk factors, angina, or regional wall motion abnormalities

Findings in DCM:

• Normal coronary arteries or non-obstructive atherosclerosis (less than 50% stenosis)
• Slow flow phenomenon may be present (microvascular dysfunction)

Modalities:

• Invasive coronary angiography: Gold standard, allows for intervention if disease found
• CT coronary angiography (CTCA): Non-invasive alternative in low-intermediate pre-test probability

Cardiac Magnetic Resonance Imaging (CMR)

Gold Standard for: [11,16]

• Precise LV and RV volumetric assessment and ejection fraction
• Myocardial tissue characterization
• Differential diagnosis of cardiomyopathies

Key CMR Sequences:

1. Cine Imaging (SSFP):

• Accurate LVEF, RVEF, ventricular volumes
• Wall motion abnormalities
• Global and regional function

2. Late Gadolinium Enhancement (LGE):

• Detects myocardial scar/fibrosis
• Mid-wall LGE pattern - characteristic of non-ischemic DCM (40-50% of patients) [11]
• Subendocardial or transmural LGE - suggests ischemic etiology
• LGE presence - strong independent predictor of adverse outcomes (SCD, ventricular arrhythmias, death) [11]

3. Native T1 and T2 Mapping:

• Native T1 elevation: Diffuse fibrosis, oedema - powerful independent predictor of adverse outcomes [27]
• T2 elevation: Myocardial oedema (active inflammation, acute myocarditis)
• Extracellular volume (ECV): Quantifies diffuse fibrosis; ECV ≥30.5% predicts worse outcomes [27,28]
• Prognostic value: T1 mapping and ECV particularly important in DCM patients without LGE, providing optimal risk stratification when combined with LGE [27,28,29]

4. T2-Weighted and T2 Imaging:*

• T2-weighted: Myocardial oedema (myocarditis, acute injury)
• T2*: Iron overload assessment (hemochromatosis, thalassemia)

Prognostic Value: [11,16]

• Mid-wall LGE: Predicts sudden cardiac death, appropriate ICD therapies, heart failure hospitalization
• Elevated native T1 and ECV: Associated with adverse remodeling and outcomes [27,28,29]
• CMR-based risk stratification enhances prediction beyond LVEF alone, with multi-parametric models integrating LGE, T1/ECV, and strain analysis [16,30]

Contraindications:

• Non-MRI compatible devices (older ICDs, pacemakers - newer devices often MRI-conditional)
• Severe renal impairment (eGFR less than 30 mL/min - caution with gadolinium)
• Claustrophobia (may require sedation)

Genetic Testing

Indications (Class I Recommendation): [4,5,7]

• All patients with DCM without clear non-genetic aetiology
• Enables cascade family screening
• Informs prognosis and management (especially LMNA, RBM20)

Testing Approach:

• Comprehensive cardiomyopathy gene panel (30-50 genes minimum) [3,5]
• Next-generation sequencing (NGS)
• Copy number variation (CNV) analysis for deletions/duplications

Interpretation:

• Pathogenic/Likely pathogenic: Disease-causing (30-50% yield) [3]
• Variant of uncertain significance (VUS): Unclear significance (common, requires family segregation)
• Negative: Does not exclude genetic cause (incomplete knowledge of all DCM genes)

Key Genes and Clinical Implications:

Endomyocardial Biopsy (EMB)

Indications (Selected Cases): [4]

• Suspected giant cell myocarditis or eosinophilic myocarditis (fulminant presentation)
• Suspected cardiac sarcoidosis (clinical and imaging findings suggestive)
• Suspected restrictive cardiomyopathy (differentiation from constrictive pericarditis)
• Unexplained new-onset heart failure less than 2 weeks with hemodynamic compromise
• Suspected storage diseases (amyloidosis, hemochromatosis, glycogen storage) if non-invasive tests inconclusive

Findings:

• Myocarditis: Inflammatory infiltrate (lymphocytic, eosinophilic, giant cell)
• Fibrosis: Interstitial or replacement fibrosis
• Idiopathic DCM: Non-specific findings (hypertrophy, fibrosis, myocyte degeneration)

Limitations:

• Invasive, sampling error (patchy disease)
• Low diagnostic yield in most DCM cases
• Not routine in typical DCM presentation

Exercise Testing (Cardiopulmonary Exercise Test - CPET)

Indications:

• Functional capacity assessment (peak VO2)
• Heart transplant evaluation (listing criteria)
• Prognostic stratification
• Exercise prescription for cardiac rehabilitation

Key Parameters:

• Peak VO2: less than 14 mL/kg/min suggests poor prognosis, transplant consideration
• VE/VCO2 slope: >35 suggests poor prognosis
• Exercise-induced arrhythmias: Prognostic significance

Holter Monitoring (24-48 Hour ECG)

Indications:

• Assess arrhythmic burden (ventricular ectopy, non-sustained VT)
• Detect paroxysmal atrial fibrillation
• Assess heart rate control in AF
• Evaluate symptoms (palpitations, syncope)

Prognostic Features:

• Non-sustained VT (NSVT) - increased SCD risk
• Frequent PVCs (>10-15% burden) - may contribute to or cause LV dysfunction
• AF detection - anticoagulation decision

Ambulatory Blood Pressure Monitoring

Indications:

• Assess blood pressure control (particularly low BP limiting up-titration of therapies)
• Identify white-coat hypertension or masked hypertension
• Evaluate symptomatic hypotension

---

7. Diagnosis and Classification

Diagnostic Criteria for DCM

ESC Definition (2016, 2023): [1,4]

A diagnosis of DCM requires:

1. Left ventricular dilation: LVEDV >97 mL/m² (men) or >90 mL/m² (women), or LVEDD >58 mm (men) or >52 mm (women)
2. Left ventricular systolic dysfunction: LVEF less than 45%
3. Absence of sufficient loading conditions or coronary artery disease to explain the degree of LV dilation and dysfunction

Exclusion Criteria:

• Obstructive coronary artery disease (>50% stenosis in major epicardial vessel) sufficient to explain LV dysfunction
• Significant valvular disease (primary valve pathology causing volume or pressure overload)
• Hypertension with LVH (although can coexist)
• Congenital heart disease
• Cor pulmonale from lung disease

Aetiological Classification

1. Familial/Genetic DCM:

• Identifiable genetic mutation or
• Two or more affected family members meeting DCM criteria [5,7]

2. Acquired DCM:

• Inflammatory (Post-myocarditis): Evidence of prior myocarditis (EMB, CMR, clinical history) [13]
• Toxic: Alcohol, chemotherapy, cocaine [2,14]
• Metabolic/Endocrine: Thyroid, nutritional deficiencies [2]
• Tachycardia-Mediated: Sustained tachyarrhythmia [15,21]
• Peripartum: Onset in last month of pregnancy or within 5 months postpartum [12]

3. Idiopathic DCM:

• No identifiable cause after comprehensive evaluation (30-40%) [2]

Phenotypic Classification

1. Classic DCM:

• LV dilation with reduced EF
• May have RV involvement

2. Arrhythmogenic DCM:

• Prominent arrhythmic phenotype (VT, VF, high ectopic burden)
• Associated genes: LMNA, RBM20, SCN5A, FLNC [5,9]

3. Hypokinetic Non-Dilated Cardiomyopathy (HNDC):

• Reduced LVEF (less than 45%) without significant LV dilation
• May represent early DCM phenotype or distinct entity

4. Left Ventricular Non-Compaction (LVNC) Overlap:

• Excessive trabeculation with DCM phenotype
• Controversial whether separate entity or morphological variant

Severity Stratification

By LVEF:

• Mild: LVEF 40-45%
• Moderate: LVEF 30-39%
• Severe: LVEF less than 30%

By NYHA Functional Class:

• Class I: No limitation, ordinary physical activity does not cause symptoms
• Class II: Slight limitation, comfortable at rest, ordinary activity causes symptoms
• Class III: Marked limitation, comfortable at rest, less than ordinary activity causes symptoms
• Class IV: Symptoms at rest, unable to carry out any physical activity without discomfort

By AHA/ACC Stages:

• Stage C: Structural heart disease with prior or current HF symptoms
• Stage D: Refractory HF requiring specialized interventions

---

8. Risk Stratification

Sudden Cardiac Death Risk Assessment

High-Risk Features: [9,17]

Clinical:

• Prior cardiac arrest or sustained VT
• Unexplained syncope
• Family history of sudden cardiac death at young age (less than 50 years)
• NYHA Class III-IV symptoms

Genetic:

• LMNA mutations: Exceptionally high risk - consider ICD even with EF >35% [9]
• RBM20 mutations: Aggressive disease, high arrhythmic risk [5]
• FLNC mutations: High arrhythmic risk [5]
• SCN5A mutations: Arrhythmias and conduction disease [5]

Imaging:

• LVEF ≤35%: Primary prevention ICD indication (after 3 months optimal therapy) [17]
• Mid-wall LGE on CMR: Independent predictor of SCD and ventricular arrhythmias [11]
• Extensive LGE (>15-20% of LV mass): Very high risk

Electrophysiological:

• Non-sustained VT on Holter monitoring
• Inducible sustained VT on electrophysiology study
• Prolonged QRS duration (>120 ms)
• Fragmented QRS

Multi-Parametric Risk Models:

• Combination of clinical, genetic, ECG, imaging, and Holter findings
• CMR-based risk stratification increasingly utilized [16,27,30]
• Machine learning approaches improve risk prediction beyond conventional criteria, identifying novel associations and reinforcing known predictors [31,32,33]
• ML-based models incorporate diverse data types for more effective stratification of high-risk DCM patients [32]

Heart Failure Prognostic Markers

Poor Prognostic Indicators: [6]

Clinical:

• Advanced age
• Male sex
• Low systolic blood pressure (less than 100 mmHg)
• Advanced NYHA class (III-IV)
• Cachexia
• Poor functional capacity (peak VO2 less than 14 mL/kg/min)

Laboratory:

• Elevated NT-proBNP (>1000 pg/mL or rising trends)
• Hyponatremia (less than 135 mmol/L)
• Renal dysfunction (eGFR less than 60 mL/min)
• Anaemia

Imaging:

• Severe LV dysfunction (LVEF less than 25%)
• Severe RV dysfunction
• Severe functional mitral regurgitation
• Elevated pulmonary artery pressures
• Mid-wall LGE on CMR [11]

Response to Therapy:

• Failure to demonstrate reverse remodeling at 3-6 months
• Recurrent hospitalizations for heart failure
• Inability to tolerate or up-titrate guideline-directed medical therapy

Reverse Remodeling Predictors

Factors Associated with LV Recovery: [10]

Favorable Indicators:

• Recent-onset disease (less than 6 months)
• Milder LV dilation at baseline
• Absence of mid-wall LGE
• Certain aetiologies: peripartum, tachycardia-mediated, inflammatory (treated myocarditis)
• TTN truncating variants (better prognosis than other genetic forms) [8]
• Early initiation of optimal medical therapy
• Young age

Recovery Potential:

• 25-40% of DCM patients show significant improvement in LVEF (increase ≥10% and final LVEF ≥50%) [10]
• Higher rates in recent-onset, peripartum, tachycardia-mediated
• Important for ICD decision-making (re-assess after 3-6 months optimal therapy)

---

9. Management

Step 1: Identify and Treat Reversible Causes

Systematic Evaluation:

Step 2: Guideline-Directed Medical Therapy (GDMT)

The Four Pillars of HFrEF Therapy: [4,18]

All four medications should be initiated and up-titrated as tolerated to target or maximally tolerated doses.

Pillar 1: RAAS Inhibition

Sacubitril/Valsartan (ARNI) - Preferred: [18]

• Evidence: PARADIGM-HF trial showed 20% reduction in CV death and HF hospitalization vs enalapril
• Dosing:
  • "Starting: 24/26 mg or 49/51 mg twice daily"
  • "Target: 97/103 mg twice daily"
• Monitoring: Potassium, renal function, blood pressure
• Caution: 36-hour washout if switching from ACE-I (angioedema risk)

ACE Inhibitors (if ARNI not tolerated/available):

• Enalapril (target 10-20 mg twice daily)
• Ramipril (target 10 mg once daily)
• Lisinopril (target 20-40 mg once daily)

ARBs (if ACE-I/ARNI not tolerated):

• Losartan (target 150 mg daily)
• Valsartan (target 160 mg twice daily)
• Candesartan (target 32 mg daily)

Pillar 2: Beta-Blockers

Evidence-Based Beta-Blockers: [18]

• Bisoprolol: Start 1.25 mg daily, target 10 mg daily
• Carvedilol: Start 3.125 mg twice daily, target 25-50 mg twice daily
• Metoprolol succinate (extended-release): Start 12.5-25 mg daily, target 200 mg daily

Initiation and Titration:

• Start low, go slow (double dose every 2-4 weeks as tolerated)
• Monitor heart rate (target 60-70 bpm), blood pressure, symptoms
• Do not stop abruptly (rebound tachycardia, ischemia)

Caution:

• May cause transient worsening of symptoms initially
• Contraindicated in decompensated HF, severe bradycardia, advanced AV block

Pillar 3: Mineralocorticoid Receptor Antagonists (MRA)

Options: [18]

• Spironolactone: Start 12.5-25 mg daily, target 25-50 mg daily
• Eplerenone: Start 25 mg daily, target 50 mg daily

Evidence: RALES (spironolactone) and EMPHASIS-HF (eplerenone) showed 30% reduction in mortality

Monitoring:

• Potassium (risk of hyperkalemia, especially with RAAS inhibition)
• Renal function
• Check K+ and creatinine at 1 week, then regularly

Caution:

• Contraindicated if K+ >5.0 mmol/L or eGFR less than 30 mL/min
• Gynecomastia with spironolactone (eplerenone preferred in men if troublesome)

Pillar 4: SGLT2 Inhibitors

Options: [18,19]

• Dapagliflozin: 10 mg once daily
• Empagliflozin: 10 mg once daily

Evidence: DAPA-HF (dapagliflozin) and EMPEROR-Reduced (empagliflozin) showed ~25% reduction in CV death and HF hospitalization, benefit irrespective of diabetes status

Mechanism: Natriuresis, favorable metabolic effects, reduced ventricular loading, improved energetics

Monitoring: Volume status, renal function, urinary tract infections, genital infections

Benefits:

• Reduced HF hospitalization
• Slowed renal function decline
• Well-tolerated, minimal drug interactions

Step 3: Additional Pharmacotherapy

Diuretics (Symptom Relief)

Loop Diuretics:

• Furosemide: 20-240+ mg daily (titrate to euvolemia)
• Bumetanide: 0.5-5 mg daily (more bioavailable)

Indications: Fluid overload, congestion Monitoring: Daily weights, electrolytes (K+, Mg2+), renal function Goal: Achieve and maintain euvolemia (dry weight)

Diuretic Resistance:

• Increase dose
• Twice-daily dosing
• Add thiazide diuretic (metolazone, bendroflumethiazide)
• IV administration (better bioavailability)

Digoxin

Indications:

• Rate control in atrial fibrillation (adjunct to beta-blocker)
• Symptomatic HFrEF despite optimal GDMT (reduces HF hospitalization, no mortality benefit)

Dosing: 62.5-250 mcg daily (lower doses, target level 0.5-0.9 ng/mL) Monitoring: Renal function, potassium, digoxin level, HR Toxicity: Nausea, confusion, visual disturbances, arrhythmias (hypokalemia and renal impairment increase risk)

Ivabradine

Indication: Sinus rhythm with HR ≥70 bpm despite maximally tolerated beta-blocker, LVEF ≤35% Dosing: 5 mg twice daily, increase to 7.5 mg twice daily if HR >60 bpm Mechanism: If channel inhibitor, pure HR reduction without negative inotropy Evidence: SHIFT trial showed reduction in HF hospitalization

Anticoagulation

Atrial Fibrillation:

• Direct oral anticoagulants (DOACs) preferred: apixaban, rivaroxaban, edoxaban, dabigatran
• Warfarin (INR 2-3) if DOAC contraindicated or mechanical valve
• CHA2DS2-VASc score typically ≥2 (anticoagulation indicated)

LV Thrombus:

• Warfarin for 3-6 months minimum (INR 2-3)
• Repeat imaging to confirm resolution
• DOACs have insufficient evidence for LV thrombus

Primary Prevention (No AF or Thrombus):

• Not routinely indicated
• Consider if very low LVEF (less than 20-25%) with severe LV dilation

Iron Supplementation

Indication: Iron deficiency (ferritin less than 100 ng/mL, or 100-300 ng/mL with transferrin saturation less than 20%) Evidence: FAIR-HF, CONFIRM-HF trials showed improved symptoms and QoL with IV iron Agent: Ferric carboxymaltose (IV) preferred over oral iron Effect: Improves symptoms, exercise capacity, quality of life (no proven mortality benefit yet)

Step 4: Device Therapy

Implantable Cardioverter-Defibrillator (ICD)

Primary Prevention Indications (Class I): [17]

• LVEF ≤35% despite ≥3 months of optimal medical therapy
• NYHA Class II-III symptoms (ambulatory)
• Life expectancy >1 year with good functional status

Special Considerations:

• LMNA mutations: Consider ICD at higher LVEF thresholds (>35%) due to extreme arrhythmic risk [9]
• Recent-onset DCM: Re-assess at 3-6 months after therapy optimization (reverse remodeling potential)
• End-stage HF (NYHA IV): ICD generally not indicated unless transplant/LVAD candidate

Secondary Prevention (Class I):

• Survivors of cardiac arrest from VF or hemodynamically unstable VT
• Sustained VT with structural heart disease

ICD Types:

• Single-chamber ICD: Adequate for most DCM patients
• Dual-chamber ICD: If bradycardia pacing also needed
• CRT-D: Combined CRT and ICD (see below)

Cardiac Resynchronization Therapy (CRT)

Indications (Class I): [4,18]

• LVEF ≤35%
• Sinus rhythm
• QRS duration ≥150 ms with LBBB morphology
• NYHA Class II-IV (ambulatory) on optimal medical therapy

Class IIa Indications:

• QRS 130-149 ms with LBBB
• QRS ≥150 ms with non-LBBB morphology (lesser benefit)

Mechanism: Resynchronizes ventricular contraction, reduces mitral regurgitation, improves hemodynamics

Evidence: CARE-HF, MADIT-CRT, RAFT trials showed:

• Improved symptoms and quality of life
• Reduced HF hospitalization
• Reduced mortality (30% relative risk reduction)
• Reverse remodeling in ~60-70% of appropriate candidates

Response Predictors:

• LBBB morphology (best response)
• QRS ≥150 ms
• Female sex
• Non-ischemic aetiology (DCM)
• Absence of extensive scar

Non-Responders: 30-40% do not show clinical or echocardiographic improvement

• Reassess lead position, consider multipoint pacing, optimize AV/VV timing

CRT-Pacemaker (CRT-P) vs CRT-Defibrillator (CRT-D):

• Most DCM patients eligible for CRT also meet ICD criteria → CRT-D
• CRT-P if ICD not indicated or declined

Permanent Pacemaker

Indications in DCM:

• Symptomatic bradycardia (sinus node dysfunction, AV block)
• High-grade or complete AV block (particularly LMNA mutations) [9]
• Atrial fibrillation with slow ventricular response

Upgrade to CRT: If high burden of RV pacing expected (>40%), consider CRT de novo to avoid RV pacing-induced dyssynchrony

Step 5: Advanced Therapies

Heart Transplantation

Indications (Stage D HF):

• Severe symptoms (NYHA Class III-IV) despite optimal medical and device therapy
• Recurrent life-threatening arrhythmias
• Cardiogenic shock or dependence on inotropic support
• Peak VO2 less than 10-12 mL/kg/min

Contraindications (Relative and Absolute):

• Advanced age (typically >70 years, varies by center)
• Pulmonary hypertension (fixed, PVR >5 Wood units unresponsive to therapy)
• Active infection or malignancy
• Irreversible end-organ dysfunction (liver, kidney)
• Severe obesity or cachexia
• Psychosocial issues, non-adherence
• Substance abuse

Evaluation: Comprehensive multi-system assessment, right heart catheterization, psychosocial evaluation

Survival: 1-year survival ~90%, 5-year ~75%, median survival ~12-14 years DCM-Specific Outcomes: Familial dilated cardiomyopathy shows excellent post-transplant survival (1-year 91%, 3-year 88%, 5-year 80%), similar to non-ischemic cardiomyopathy and superior to ischemic cardiomyopathy [36]

Left Ventricular Assist Device (LVAD)

Indications:

• Bridge to Transplant (BTT): Decompensated HF, transplant candidate, waiting for donor organ
• Destination Therapy (DT): End-stage HF, not transplant candidate, INTERMACS 1-4
• Bridge to Decision: Unclear candidacy, support while evaluating for transplant
• Bridge to Recovery: Expectation of myocardial recovery (rare in DCM - more common in acute myocarditis)

Types:

• Continuous-flow LVADs (current generation): HeartMate 3, HeartWare HVAD (withdrawn from market)
• Centrifugal or axial flow pumps
• Improved hemocompatibility and reduced thrombosis/bleeding in newer devices [34]

Outcomes:

• Improved survival compared to medical therapy in advanced HF
• 2-year survival ~80% for BTT, ~60% for DT [34,35]
• Ischemic vs non-ischemic etiology: Similar 30-day (94-95%), 6-month (85-92%), and 1-year (82-89%) survival rates [35]
• Complications: Stroke, bleeding (GI bleeding, epistaxis), infection (driveline), pump thrombosis, RV failure

Quality of Life: Significant improvement in symptoms and functional status

Contraindications: Severe RV failure, significant aortic regurgitation, severe peripheral vascular disease, active infection

Other Advanced Therapies

Inotropic Support (Palliative or Bridge):

• Dobutamine, milrinone (intermittent or continuous infusions)
• For end-stage symptoms, bridge to transplant/LVAD, or palliative care

Surgical Mitral Valve Repair/Replacement:

• Selected patients with severe functional MR despite optimal therapy
• Controversial benefit; consider if other valve pathology contributing

Step 6: Genetic Testing and Family Screening

Genetic Testing (Class I): [4,5,7]

• All DCM patients without clear non-genetic aetiology
• Comprehensive cardiomyopathy gene panel
• Pre-test genetic counseling recommended
• Post-test counseling to discuss implications

Cascade Family Screening (Class I): [7]

If Genetic Mutation Identified:

• Offer predictive genetic testing to first-degree relatives
• If mutation-positive: Clinical screening from age 10 years (or earlier if symptomatic)
• If mutation-negative: No further screening required (assuming correct familial variant)

If No Mutation Identified or Genetic Testing Not Done:

• Clinical screening of all first-degree relatives
• Baseline: ECG and echocardiography
• Frequency:
  • Every 3-5 years from age 10 years if asymptomatic
  • More frequent if borderline changes
  • Symptom-triggered screening at any time

Second-Degree Relatives:

• Screen if multiple affected family members or early-onset disease in family

Step 7: Lifestyle and Supportive Measures

Alcohol:

• Complete abstinence if alcohol-induced DCM
• Moderation in all DCM patients (less than 14 units/week per UK guidelines, many advocate complete avoidance)

Exercise:

• Moderate aerobic exercise recommended (cardiac rehabilitation programs)
• Avoid competitive sports or intense isometric exercise (unless very mild disease and discussed with cardiologist)
• Exercise training improves functional capacity and quality of life

Diet:

• Sodium restriction (2-3 g/day) if fluid retention
• Fluid restriction (1.5-2 L/day) if severe HF or hyponatremia
• Heart-healthy diet (Mediterranean-style diet)

Weight Management:

• Achieve and maintain healthy BMI
• Daily weights (report gain >2-3 kg in 1-3 days)

Smoking Cessation:

• Critical - smoking cessation support

Immunizations:

• Annual influenza vaccine
• Pneumococcal vaccine (PCV13 and PPSV23)
• COVID-19 vaccination

Pregnancy Counseling: [12]

• High-risk if LVEF less than 45% or symptomatic HF
• Pre-conception counseling essential
• Multidisciplinary care (cardiology, obstetrics, anaesthetics)
• Avoid ACE-I/ARBs (teratogenic), replace with hydralazine-nitrate, beta-blocker
• Peripartum DCM risk if prior DCM - avoid future pregnancy if incomplete recovery

Driving:

• Varies by jurisdiction
• Typically restricted after ICD implantation (6 months for primary prevention, longer for secondary)
• Commercial/vocational driving usually prohibited with LVEF less than 40% or ICD

Psychological Support:

• Depression common in chronic HF (30-40%)
• Screen for depression and anxiety
• Psychological support, counseling, antidepressant therapy if indicated

---

10. Monitoring and Follow-Up

Initial Intensive Phase (First 3-6 Months)

Frequency: Every 2-4 weeks during medication titration

Assessments:

• Clinical status (symptoms, functional class, fluid status)
• Blood pressure and heart rate
• Weight
• Blood tests: U&E, eGFR, K+, Mg2+ (1 week after starting/changing RAAS inhibitor or MRA, then regularly)
• Adherence to medications

Goals:

• Achieve euvolemia
• Up-titrate GDMT to target or maximally tolerated doses
• Optimize device therapy settings if applicable

Stable Phase Follow-Up

Frequency: Every 3-6 months if stable

Clinic Visits:

• Clinical assessment (NYHA class, symptoms)
• Medication review and adherence
• Blood tests (U&E, eGFR, NT-proBNP)
• ECG (rhythm, conduction)

Echocardiography:

• 3-6 months after initial diagnosis and GDMT optimization (assess reverse remodeling)
• Annually if stable
• As needed if clinical deterioration

Additional Investigations:

• Holter monitoring: As needed for arrhythmia evaluation
• CMR: Not routine; consider if prognostic information needed or change in clinical status
• CPET: If considering transplant or assessing functional capacity

Device Clinic Follow-Up

ICD/CRT:

• Remote monitoring (wireless transmission) - alerts for arrhythmias, device parameters
• In-person device checks every 6-12 months

Monitoring for:

• Appropriate/inappropriate ICD therapies
• Battery status
• Lead integrity
• CRT response (% biventricular pacing >95% desirable)

Red Flags During Follow-Up (Require Urgent Review)

• Worsening symptoms or functional decline
• Recurrent HF hospitalization
• Sustained arrhythmias or ICD shocks
• Syncope
• Progressive renal dysfunction or electrolyte abnormalities
• Inability to tolerate GDMT (persistent hypotension, bradycardia)
• Escalating diuretic requirements
• Development of new comorbidities

---

11. Complications

Arrhythmic Complications

Thromboembolic Complications

Left Ventricular Thrombus:

• Incidence: 10-15% of DCM patients with severe LV dysfunction, particularly apical akinesis/aneurysm
• Risk Factors: Very low LVEF (less than 25%), AF, apical akinesis
• Screening: Echocardiography (apical views), cardiac MRI (more sensitive)
• Management: Anticoagulation (warfarin 3-6 months minimum, INR 2-3), repeat imaging

Stroke/Systemic Embolism:

• Incidence: 2-3% per year
• Risk Factors: AF, LV thrombus, very low LVEF
• Prevention: Anticoagulation for AF (DOACs), warfarin for LV thrombus

Heart Failure Progression

Chronic HF:

• Progressive symptoms despite optimal therapy
• Reduced quality of life
• Recurrent hospitalizations (average 1-2 per year in moderate-severe HF)

Acute Decompensated HF:

• Triggers: Non-adherence, infections, arrhythmias, dietary indiscretion, renal dysfunction
• Management: IV diuretics, vasodilators, inotropes if needed, treat precipitant

Cardiogenic Shock:

• End-stage manifestation
• Requires intensive monitoring, inotropic support, consideration of mechanical circulatory support (IABP, Impella, VA-ECMO, LVAD)

End-Organ Dysfunction

Cardiorenal Syndrome:

• Worsening renal function in setting of worsening HF (type 1) or chronic HF (type 2)
• Multifactorial: Low cardiac output, venous congestion, RAAS activation, diuretic resistance
• Management: Optimize hemodynamics, judicious diuresis, ultrafiltration if refractory

Hepatic Dysfunction:

• Congestive hepatopathy from chronic passive congestion
• Elevated transaminases, bilirubin
• "Cardiac cirrhosis" in severe chronic cases

Cachexia:

• Severe unintentional weight loss (muscle and fat)
• Poor prognostic sign
• Multifactorial: Reduced intake, malabsorption, inflammation, hypermetabolism
• Nutritional support, address reversible causes

Right Ventricular Failure

Secondary to Pulmonary Hypertension:

• Chronic LV dysfunction → elevated LA pressure → pulmonary venous hypertension → pulmonary arterial hypertension → RV failure
• Signs: Elevated JVP, peripheral oedema, hepatomegaly, ascites
• Poor prognosis
• Management: Optimize LV function, diuretics; pulmonary vasodilators generally not effective in HF-PH

Other Complications

Depression and Anxiety:

• Incidence: 30-40%
• Impact on quality of life, adherence, outcomes
• Screen regularly, offer psychological support, antidepressants if indicated

Device-Related Complications:

• ICD shocks (appropriate and inappropriate)
• Lead fracture or dislodgement
• Infection (device pocket, endocarditis)
• Pneumothorax (implantation complication)

---

12. Prognosis

Overall Survival

Modern Era (with GDMT): [6]

• 1-year survival: 85-90%
• 5-year survival: 60-80%
• 10-year survival: 40-50%

Significant Improvement: Historical (pre-GDMT era) 5-year survival was ~25-40%; modern quadruple therapy has dramatically improved outcomes [18,19]

Prognostic Stratification

Good Prognosis:

• Recent-onset DCM (less than 6 months)
• Reversible aetiology (tachycardia-mediated, peripartum, alcohol with abstinence)
• Milder LV dysfunction (LVEF 35-45%)
• Young age
• Absence of mid-wall LGE [11]
• TTN truncating variants (better than other genetic forms) [8]
• Significant reverse remodeling with therapy [10]

Poor Prognosis:

• Advanced age
• Severe LV dysfunction (LVEF less than 25%)
• RV dysfunction
• Persistent symptoms despite optimal therapy (NYHA III-IV)
• Recurrent HF hospitalizations
• Low systolic blood pressure (less than 100 mmHg)
• Worsening renal function
• Hyponatremia (less than 135 mmol/L)
• Elevated NT-proBNP (>1000 pg/mL) or rising levels
• Low peak VO2 (less than 12-14 mL/kg/min)
• Mid-wall LGE on CMR [11,16]
• LMNA or RBM20 mutations [5,9]
• Failure to demonstrate reverse remodeling

Gene-Specific Prognosis

Reverse Remodeling and Recovery

Definition: Increase in LVEF ≥10% and final LVEF ≥50%, or normalization of LV size [10]

Incidence: 25-40% of DCM patients show significant reverse remodeling with optimal therapy [10]

Predictors of Recovery:

• Recent-onset disease
• Specific aetiologies: peripartum (50-70% recovery), tachycardia-mediated (60-80% recovery), post-myocarditis (variable)
• Absence of mid-wall LGE
• Younger age
• Female sex (peripartum context)
• TTN mutations (better than other genetic causes)

Implications:

• May allow de-escalation of some therapies (e.g., ICD removal if sustained EF >35% for >6-12 months - controversial)
• Genetic DCM: Relapse possible, continue GDMT indefinitely

Sudden Cardiac Death Risk

Annual Risk:

• Overall DCM population: 2-5% per year
• LVEF ≤35%: 5-10% per year without ICD
• LMNA mutations: Up to 10-15% per year [9]

ICD Impact: Primary prevention ICD reduces SCD by ~50-70% in appropriate candidates [17]

Heart Transplant Outcomes

If Listed for Transplantation:

• Waiting time variable (blood group, size, urgency - UNOS status)
• Post-transplant survival: 1-year ~90%, 5-year ~75%, median ~12-14 years

---

13. Special Populations

Peripartum Cardiomyopathy

Definition: DCM developing in last month of pregnancy or within 5 months postpartum without other identifiable cause [12]

Epidemiology:

• Incidence: 1:1000-4000 deliveries (higher in Sub-Saharan Africa, Haiti)
• Risk factors: Multiparity, advanced maternal age (>30 years), African descent, multiple gestation, pre-eclampsia, hypertension

Pathophysiology: Multifactorial - anti-angiogenic factors (sFlt-1, cleaved prolactin), increased hemodynamic stress, inflammation

Management:

• Standard HF therapy (beta-blockers, diuretics, hydralazine-nitrate instead of ACE-I during pregnancy/breastfeeding)
• Bromocriptine: Prolactin inhibition may aid recovery (2.5 mg twice daily for 2-8 weeks) - evidence from small trials
• Anticoagulation: Consider if LVEF less than 30% (increased thrombotic risk in pregnancy/postpartum)

Prognosis:

• 50-70% recover to normal or near-normal LVEF within 6 months
• Non-recovery: Persistent DCM, worse prognosis
• Future pregnancies: High risk of relapse (25-50%), particularly if incomplete recovery - generally advised against

Paediatric DCM

Differences from Adult:

• Higher proportion of genetic and metabolic causes
• Syndromic presentations more common (Barth syndrome, mitochondrial disorders, muscular dystrophies)
• Rapid progression possible
• Transplant often needed earlier

Genetic Testing: Essential in all pediatric cases Family Screening: Cascade screening from early age (tailored to specific genetic mutation)

LMNA Cardiomyopathy (High-Risk Subtype)

Clinical Features: [9]

• Arrhythmias: Atrial fibrillation, ventricular arrhythmias, high SCD risk
• Conduction disease: Progressive AV block (may require pacing)
• Skeletal myopathy: Limb-girdle muscular dystrophy (LMNA overlaps)
• Metabolic: Lipodystrophy, insulin resistance (some variants)

Management Differences:

• Early ICD: Consider even if LVEF >35% (very high arrhythmic risk)
• Pacemaker: Often needed for progressive conduction disease
• Close Monitoring: Regular Holter, ECG for conduction changes
• Transplant: Earlier referral (poor prognosis, median transplant-free survival ~50% at 5 years)

Prognosis: Among worst of genetic DCM subtypes

Elderly Patients

Challenges:

• Higher comorbidity burden
• Polypharmacy
• Frailty
• Lower tolerance of medications (hypotension, bradycardia)

Management Considerations:

• Individualized GDMT targets (may not tolerate full doses)
• Device therapy: Still beneficial if life expectancy >1 year
• Careful monitoring of renal function and electrolytes
• Address geriatric syndromes (falls, cognitive impairment, social support)

---

14. Emerging Therapies and Research

Novel Pharmacotherapies

Vericiguat (Soluble Guanylate Cyclase Stimulator):

• VICTORIA trial: Reduction in CV death/HF hospitalization in worsening HF with LVEF less than 45% [37]
• Particular benefit in high-risk patients with recent HF hospitalization
• Not yet widely adopted; may have role in advanced HF despite GDMT

Omecamtiv Mecarbil (Cardiac Myosin Activator):

• GALACTIC-HF: Reduction in HF events in HFrEF [38]
• Novel mechanism: Increases systolic ejection time without increasing oxygen consumption
• Larger benefit in patients with severe HF and higher NT-proBNP levels [38]

Gene Therapy:

• Preclinical and early clinical trials
• Targets: SERCA2a gene delivery, specific genetic corrections (e.g., CRISPR for genetic DCM)

Advanced Imaging

CMR Refinement:

• Native T1, T2, ECV mapping for detecting early disease, guiding treatment, monitoring [27,28,29]
• CMR-based risk scores integrating LGE, strain, volumes [16,30]
• Multi-parametric tissue characterization enhances prognostic stratification

Positron Emission Tomography (PET):

• Metabolic imaging, inflammation detection (sarcoidosis, myocarditis)
• FDG-PET for viability assessment

Precision Medicine

Genotype-Specific Therapies:

• Targeted treatments based on genetic subtype (e.g., elamipretide for mitochondrial cardiomyopathy - early trials)
• RNA-based therapies (antisense oligonucleotides, siRNA) for specific mutations

Risk Prediction Models:

• Multi-parametric models integrating clinical, genetic, imaging, biomarker data
• Machine learning approaches to predict outcomes and therapy response, identifying novel risk associations beyond conventional criteria [22,31,32,33]
• ML-based ECG analysis can stratify DCM subgroups by disease progression and genetic background [33]

Regenerative Medicine

Stem Cell Therapy:

• Cardiosphere-derived cells, mesenchymal stem cells
• Limited efficacy in trials to date; research ongoing

Cardiac Tissue Engineering:

• Engineered heart tissue patches
• Preclinical stages

Improved Device Therapies

Leadless Pacing and CRT:

• Wireless pacing systems
• Conduction system pacing (His bundle, left bundle branch pacing) - alternative to biventricular pacing

Next-Generation LVADs:

• Fully implantable, smaller devices
• Improved hemocompatibility (reduced thrombosis and bleeding)

---

15. Patient Education and Layperson Explanation

What is Dilated Cardiomyopathy?

Dilated cardiomyopathy (DCM) is a condition where the main pumping chamber of your heart (the left ventricle) becomes enlarged and weakened. When the heart muscle stretches and becomes thinner, it cannot pump blood around your body as effectively as it should. This leads to symptoms of heart failure, such as breathlessness, tiredness, and swelling of the legs.

What Causes Dilated Cardiomyopathy?

DCM can have many different causes:

Genetic (Inherited):

• About 30-50% of people with DCM have a genetic cause
• Specific genes that control heart muscle function have changes (mutations)
• DCM can run in families - your relatives may also be at risk

Acquired (Developed Over Time):

• Viral infections: Some people develop DCM after a heart infection
• Alcohol: Drinking too much alcohol over many years can damage the heart muscle
• Pregnancy: Rarely, DCM can develop during or after pregnancy (peripartum cardiomyopathy)
• Medications: Some chemotherapy drugs can affect the heart
• Fast heart rhythms: If your heart beats too fast for a long time, it can become weakened

Unknown (Idiopathic):

• In 30-40% of people, we cannot find a specific cause even after thorough testing

Why Does Genetic Testing Matter?

If we find a genetic cause for your DCM:

• We can test your family members (parents, siblings, children) to see if they carry the same genetic change
• If they do, we can monitor them closely with regular heart scans and start treatment early if their heart starts to change
• Early detection in family members can prevent them from developing symptoms and improve their long-term health

How is DCM Treated?

Medications: Modern treatment involves four main types of medication that work together to help your heart:

1. ACE inhibitors or Angiotensin Receptor-Neprilysin Inhibitors (ARNIs): Reduce the work your heart has to do
2. Beta-blockers: Slow your heart rate and reduce strain on the heart
3. Mineralocorticoid Receptor Antagonists (MRAs): Remove extra fluid and protect the heart
4. SGLT2 Inhibitors: Originally diabetes drugs, but help everyone with heart failure by improving heart function

These medications have been proven to help people live longer and feel better. It's important to take them regularly, even if you feel well.

Devices:

• Implantable Cardioverter-Defibrillator (ICD): A small device implanted under the skin that monitors your heart rhythm and can deliver a life-saving shock if your heart develops a dangerous rhythm
• Cardiac Resynchronization Therapy (CRT): A special pacemaker that helps both sides of your heart beat in a coordinated way, improving pump function

Advanced Treatments (for Severe Cases):

• Left Ventricular Assist Device (LVAD): A mechanical pump that helps your heart pump blood
• Heart Transplant: Replacing your heart with a donor heart if medications and devices are not enough

Lifestyle Changes

Stop Alcohol Completely (Especially if Alcohol-Related):

• If alcohol caused your DCM, stopping drinking can allow your heart to recover
• Even if alcohol wasn't the cause, it's best to limit or avoid alcohol

Stop Smoking:

• Smoking damages blood vessels and makes heart problems worse
• Seek help to quit

Exercise:

• Gentle to moderate exercise is good for your heart and helps you feel better
• Cardiac rehabilitation programs provide supervised, safe exercise
• Avoid very intense exercise or competitive sports

Diet:

• Eat a heart-healthy diet with plenty of fruits, vegetables, whole grains, and lean proteins
• Limit salt (sodium) to reduce fluid buildup (aim for less than 2-3 grams per day if you have swelling)
• Monitor your weight daily - report sudden weight gain (more than 2 kg in a few days)

Vaccinations:

• Get flu vaccine every year
• Get pneumonia vaccine (protects from chest infections)
• COVID-19 vaccine as recommended

What About Pregnancy?

If you are a woman with DCM:

• Pregnancy puts extra strain on the heart
• If your heart function is reduced (LVEF less than 45%), pregnancy is high risk
• Discuss with your cardiologist before getting pregnant
• Some heart medications cannot be used during pregnancy and need to be changed
• If you develop DCM during or after pregnancy (peripartum cardiomyopathy), there is a good chance of recovery, but future pregnancies are risky

What is the Outlook (Prognosis)?

The outlook for DCM has improved dramatically in recent years with modern treatments:

• With the best medical therapy, many people live for many years with good quality of life
• Some people (25-40%) see their heart function improve or even return to normal, especially if DCM is caught early
• Factors that affect outlook include:
  • "Better outlook: Younger age, recent-onset disease, treatable cause, good response to medications"
  • "More challenging: Severe heart function reduction, genetic types with high arrhythmia risk (like LMNA), no improvement with treatment"

When to Seek Urgent Medical Attention

Contact your doctor or emergency services immediately if you experience:

• Severe breathlessness that is new or suddenly worse
• Chest pain
• Fainting or near-fainting (possible dangerous heart rhythm)
• Sudden leg swelling, pain, or redness (possible blood clot)
• Sudden weight gain (>2-3 kg in a few days)
• ICD shock (if you have a defibrillator) - feels like a sudden thump in the chest

Family Screening

If you have DCM, your first-degree relatives (parents, siblings, children) should be offered:

• Heart scan (echocardiogram) and ECG
• Repeat screening every 3-5 years if normal (or sooner if symptoms develop)
• Genetic testing if a mutation is found in you

Early detection in family members can be life-saving.

Living with DCM

• Take your medications every day, even when you feel well
• Attend all your appointments
• Monitor your symptoms and weight
• Stay active (gentle exercise)
• Eat a healthy diet and limit salt
• Avoid alcohol
• Get vaccinated
• Seek support if you feel anxious or depressed - this is common and help is available
• Join patient support groups (e.g., Cardiomyopathy UK) for information and peer support

---

16. Key Guidelines and Evidence Base

Major Guidelines

Landmark Clinical Trials

Medical Therapy:

Device Therapy:

Genetics and Imaging:

---

17. References

1. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-1858. PMID: 26792875

2. Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5(1):32. PMID: 31123266

3. Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19(2):192-203. PMID: 27532257

4. Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013;62(22):2046-2072. PMID: 23500312

5. Jordan E, Peterson L, Ai T, et al. Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation. 2021;144(1):7-19. PMID: 33947203

6. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61-73. PMID: 30429050

7. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281-302. PMID: 29567238

8. Tayal U, Newsome S, Buchan R, et al. Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol. 2017;69(19):2466-2468. PMID: 28494984

9. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. J Am Coll Cardiol. 2016;68(21):2299-2307. PMID: 27884248

10. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57(13):1468-1476. PMID: 21435518

11. Halliday BP, Gulati A, Ali A, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017;135(22):2106-2115. PMID: 28373528

12. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(2):207-221. PMID: 31918837

13. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648. PMID: 23824828

14. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-2801. PMID: 27567406

15. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110(3):247-252. PMID: 15238462

16. Puntmann VO, Carr-White G, Jabbour A, et al. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovasc Imaging. 2016;9(1):40-50. PMID: 26762873

17. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2018;138(13):e272-e391. PMID: 29084731

18. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421. PMID: 35379503

19. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. PMID: 32877652

20. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531-547. PMID: 23900355

21. Shoureshi P, Tan AY, Koneru J, Ellenbogen KA, Kaszala K, Huizar JF. Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(23):2249-2261. PMID: 38811098

22. Parikh VN, Day SM, Lakdawala NK, Adler ED, Olivotto I, Seidman CE, Ho CY. Advances in the study and treatment of genetic cardiomyopathies. Cell. 2025;188(4):1054-1074. PMID: 39983674

23. Peoples JN, Saraf A, Ghazal N, Pham TT, Kwong JQ. Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy. Front Cell Dev Biol. 2021;8:624216. PMID: 33511136

24. Luczak ED, Anderson ME. CaMKII oxidative activation and the pathogenesis of cardiac disease. J Mol Cell Cardiol. 2014;73:112-116. PMID: 24513040

25. Luczak ED, Wu Y, Granger JM, et al. Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy. Nat Commun. 2020;11(1):4416. PMID: 32887881

26. Stolen KQ, Kemppainen J, Ukkonen H, et al. Myocardial oxidative metabolic supply-demand relationships in patients with nonischemic dilated cardiomyopathy. J Nucl Cardiol. 2006;13(4):534-542. PMID: 16919578

27. Li S, Zhou D, Sirajuddin A, et al. T1 Mapping and Extracellular Volume Fraction in Dilated Cardiomyopathy: A Prognosis Study. JACC Cardiovasc Imaging. 2022;15(4):578-590. PMID: 34538631

28. Liang K, Baritussio A, Palazzuoli A, et al. Prognostic value of cardiovascular magnetic resonance T1 mapping and extracellular volume fraction in nonischemic dilated cardiomyopathy. Clin Radiol. 2023;78(3):e146-e155. PMID: 36747201

29. Soltani MD, Meucci MC, Narang A, et al. Utility of native T1 mapping and myocardial extracellular volume fraction in patients with nonischemic dilated cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm. 2024;21(6):877-886. PMID: 38371310

30. Chatzantonis G, Bietenbeck M, Elsanhoury A, et al. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol. 2021;110(4):555-568. PMID: 33447912

31. Krittanawong C, Johnson KW, Rosenson RS, et al. Machine learning in sudden cardiac death risk prediction: a systematic review. Europace. 2023;25(2):748-764. PMID: 36201237

32. Feeny AK, Rickard J, Patel D, et al. A machine-learning-based method to predict adverse events in patients with dilated cardiomyopathy and severely reduced ejection fractions. Circ Arrhythm Electrophysiol. 2021;14(10):e009555. PMID: 34464552

33. Gigli M, Merlo M, Graw SL, et al. Clustering in dilated cardiomyopathy at initial evaluation: An effective tool for clinical stratification. Eur J Heart Fail. 2025;27(1):147-157. PMID: 40815543

34. Schmitto JD, Hanke JS, Rojas SV, et al. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Heart Lung Transplant. 2015;34(6):858-860. PMID: 25704868

35. Topilsky Y, Oh JK, Shah DK, et al. Ischemic versus nonischemic dilated cardiomyopathy: the implications of heart failure etiology on left ventricular assist device outcomes. J Heart Lung Transplant. 2013;32(6):628-633. PMID: 23438774

36. Halliday BP, Baksi AJ, Gulati A, et al. Contemporary characteristics and outcomes of adults with familial dilated cardiomyopathy listed for heart transplantation. J Heart Lung Transplant. 2019;38(3):249-259. PMID: 30705741

37. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. PMID: 32222134

38. Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail. 2020;8(4):329-340. PMID: 32035892

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. It does not replace professional medical judgement. Always consult current guidelines and specialist advice for individual patient management.